Seaport Therapeutics Unknown · $15M raised · (2026)

Seaport Therapeutics has secured up to $15 million from ARPA-H to develop GlyphCele™, an oral therapeutic aimed at restoring gut lymphatic function. This funding will support the advancement of their novel treatment, which is the first of its kind designed for this specific therapeutic goal. The partnership with Monash Institute of Pharmaceutical Sciences is also highlighted in this award.